Simvastatin
Simvastatin is a statin, a medicine taken by mouth to lower LDL cholesterol. The FDA label says it is indicated to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia. Zocor is the brand name on the label read.
Also called Zocor
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 36567; UNII AGG2FN16EV. MeSH descriptor D019821 is Simvastatin. Class: HMG-CoA Reductase Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Organon LLC label for ZOCOR (simvastatin), application NDA019766, effective 2025-03-28 in openFDA. This page records the label indication and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 11
- Phase 3 or 4
- 8
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 2/3 | 1 | 0 | 0 | 1 |
| Phase 3 | 4 | 2 | 0 | 6 |
| Phase 4 | 1 | 0 | 1 | 2 |
| No phase | 1 | 0 | 0 | 1 |
| All phases | 8 | 2 | 1 | 11 |
Conditions these trials study
- Dyslipidemia
- High cholesterol (hypercholesterolemia)
- Atherosclerosis
- Chronic kidney disease (CKD)
- Subarachnoid hemorrhage
- Type 2 diabetes
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of simvastatin lists an indication: adults with primary hyperlipidemia
- Recipient
- Adult
- Population
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol (LDL cholesterol) indication.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passage read states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with primary hyperlipidemia
- Excluded
- None stated
The US label of ZOCOR (simvastatin), in the Organon LLC version dated 2025-03-28 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.
Applies to Adult People for whom the US label of simvastatin lists an indication: adults with primary hyperlipidemia
- Certainty method
- Not assessed
- Limitations
- This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-07
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that gives the LDL-cholesterol indication.
- Retrieved
- Source effective date
- 2025-03-28
- Source state
- Current
- Version fingerprint
e61cb84d9362069369e2e6ca98bae80f77907ec3102d10a9c5fc1fd15918f843- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250328.
- Retrieved
- Source effective date
- 2025-03-28
- Source state
- Current
- Version fingerprint
e61cb84d9362069369e2e6ca98bae80f77907ec3102d10a9c5fc1fd15918f843- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.
FLOLIPID
No label from the application holder was found in the openFDA label dataset for application NDA206679. This page does not show another labeler's label in its place.
JUVISYNC
No label from the application holder was found in the openFDA label dataset for application NDA202343. This page does not show another labeler's label in its place.
SIMVASTATIN
No label from the application holder was found in the openFDA label dataset for application NDA021961. This page does not show another labeler's label in its place.
VYTORIN
- Application
- NDA021687
- Labeler
- Organon LLC
- Label version
- Version 9, effective
- Label set id
89b860d2-de83-468e-b7e8-76aeec2edca2- Boxed warning
- No boxed warning
- Sections the label has
- Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies
ZOCOR
No label from the application holder was found in the openFDA label dataset for application NDA019766. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Supplemental approval
NDA019766 - Approval
NDA021687 - Supplemental approval
NDA021687 - Supplemental approval
NDA021687 - Approval
NDA021961 - Supplemental approval
NDA021687 - Approval
NDA202343 - Supplemental approval
NDA021687 - Supplemental approval
NDA202343 - Approval
NDA206679
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists lowering LDL cholesterol as an indication: Dyslipidemia
Applies to Adult People for whom the US label of simvastatin lists an indication: adults with primary hyperlipidemia
The US label of ZOCOR (simvastatin), in the Organon LLC version dated 2025-03-28 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 5
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 13 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 11
Record details
- Record id
cardio:simvastatin- Content hash
d9ed39968fca3c0577509e7c0b5da8df36337c6694f25d6b9ff8c87bbdb82110